Compare AstraZeneca plc (AZN) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Nokia Corp — how do they compare? AstraZeneca plc trades at $168.43 (market cap $253.13B), while Nokia Corp trades at $11.36 (market cap $65.32B). The key difference: AstraZeneca plc is far larger — about 3.9× Nokia Corp's market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | NOK | |
|---|---|---|
Market Cap | $253.13B | $65.32B |
Sector | Health | Technology |
52-Week High | $209.48 | $16.83 |
52-Week Low | $137.44 | $4.05 |
Enterprise Value | $279.37B | $62.14B |
Dividend Yield | 1.92% | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Nokia (NOK) trades at $11.675, down 6.04% today amid a broader technical pullback despite strong AI-driven momentum. The stock has surged over 100% YTD on AI infrastructure partnerships, including a $1 billion deal with Nvidia. Recent earnings show mixed results with Q1 2026 missing expectations, but Q3 and Q4 2025 beat estimates. Valuation metrics appear elevated with a P/E of 73.32, while profitability remains modest with a 3.98% net margin. Cash flow trends show volatility, with 2025 net cash flow negative at -$1.16 billion.
Nokia's AI transformation presents significant upside potential with analyst consensus target of $18.00 (54% upside), but high valuation and execution risks warrant caution. The company's pivot to AI networking infrastructure is gaining traction, though supply constraints and heavy R&D spending could pressure near-term profitability. Technical indicators suggest near-term bearish pressure with key support at $11.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
